XML 155 R43.htm IDEA: XBRL DOCUMENT v3.24.4
BASIS OF PRESENTATION (Details Narrative) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2023
Mar. 31, 2023
Net loss $ (6,639,935) $ (4,790,597) $ (18,542,654) $ (13,830,371)        
Net cash used in operations     14,998,919          
Working capital     12,285,310          
Amortization of right-of-use assets 22,507 102,549 23,686 85,696        
Accumulated deficit $ (104,479,192)   (91,644,233) (66,232,813)        
Description of the warrants and reduced the exercise price which the Company issued 9,748,252 new warrants and reduced the exercise price of 4,874,126 warrant shares from $1.45 to $0.8701 to induce exercise and receive gross cash proceeds of $4,240,977              
Stockholders' equity $ 34,976,599 $ 44,195,740 $ 36,043,028 $ 39,284,295 $ 32,119,574 $ 34,546,682 $ 43,669,058 $ 44,007,783
CANA Pharmaceutical Laboratories, S.A. ("Cana") [Member]                
Net cash used in operations 3,883,215              
Working capital 11,027,653              
Amortization of right-of-use assets 1,588,163              
Cash proceed $ 629,426              
Proceeds from sale of common stock 901,488